Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic
pharmaceutical company focused on the discovery, development and
commercialization of first-in-class therapies for the treatment of
patients with open-angle glaucoma, retinal diseases and other
diseases of the eye today announced the appointment of David Ellis,
Ph.D., as Director, Chemistry, reporting to Mitchell deLong, Ph.D.,
Aerie’s Vice President of Chemistry. Dr. Ellis will be responsible
for advancing the Company’s creation and optimization of new
chemical entities to support the growth and advancement of Aerie’s
pipeline. Dr. Ellis most recently held a related position at
Novartis. Aerie also announced the appointments of Angela Justice
as Western Regional Director, Medical Science Liaison and Brian
Sakurada, PharmD, Director, Scientific Market Access, both
reporting to Welyn Bui, PharmD, Aerie’s Vice President of Medical
Affairs. Ms. Justice will be responsible for leading a regional
team of Medical Science Liaisons engaged in developing
relationships with medical experts in the field of glaucoma to
ensure a fair and balanced exchange of scientific, clinical and
medical information. Ms. Justice most recently held a related
position at Sun Pharmaceuticals. Dr. Sakurada will be responsible
for further developing the medical affairs strategy including
delivery of evidence-based scientific information and outcome-based
information to national and regional payer accounts. Dr. Sakurada
most recently held a related position at Intarcia Therapeutics.
Aerie also announced the appointment of Karisma Sharma as Vice
President, Human Resources, reporting to Kathy McGinley, Aerie’s
Vice President of Human Resources and Corporate Services. Ms.
Sharma will be responsible for leading the strategic human
resources effort to recruit, develop and retain employees in the
United States. Ms. Sharma previously held related positions in both
healthcare and technology companies.
In connection with their acceptance of their positions, Dr.
Ellis, Ms. Justice, Dr. Sakurada and Ms. Sharma will receive
combined awards totaling 87,260 stock options and 2,000 shares of
restricted stock. The stock options will vest over 4 years, with
25% vesting on the first anniversary of the hire date and the
remainder vesting ratably on each of the subsequent 36 monthly
anniversaries of the hire date; the restricted stock will vest over
a period of 4 years in four equal annual installments on each
anniversary of the hire date. This award was made outside of
Aerie’s stockholder-approved equity incentive plan and was approved
by the Company’s independent directors as inducements material to
Dr. Ellis, Ms. Justice, Dr. Sakurada and Ms. Sharma entering into
employment with the Company in reliance on NASDAQ Listing Rule
5635(c)(4), which requires this public announcement.
About Aerie Pharmaceuticals, Inc.
Aerie is an ophthalmic pharmaceutical company focused on the
discovery, development and commercialization of first-in-class
therapies for the treatment of patients with open-angle glaucoma,
retinal diseases and other diseases of the eye. Aerie's first
product, Rhopressa®(netarsudil ophthalmic solution) 0.02%, a
once-daily eyedrop approved by the U.S. Food and Drug
Administration (FDA) for the reduction of elevated intraocular
pressure (IOP) in patients with open-angle glaucoma or ocular
hypertension, was launched in the United
States in April 2018. In clinical trials of Rhopressa®,
the most common adverse reactions were conjunctival hyperemia,
corneal verticillata, instillation site pain, and conjunctival
hemorrhage. More information about Rhopressa®, including the
product label, is available at www.rhopressa.com. Aerie’s
second product for the reduction of elevated intraocular pressure
(IOP) in patients with open-angle glaucoma or ocular hypertension,
Rocklatan™ (netarsudil and latanoprost ophthalmic solution)
0.02%/0.005%, the first and only fixed-dose combination of
Rhopressa® and the
widely-prescribed PGA (prostaglandin analog) latanoprost,
has been approved by the FDA and is expected to be
launched in the United States in the second quarter of 2019.
In clinical trials of Rocklatan™, the most common adverse
reactions were conjunctival hyperemia, corneal verticillata,
instillation site pain, and conjunctival hemorrhage. More
information about Rocklatan™, including the product label, is
available at www.rocklatan.com. Aerie continues to focus on
global expansion and the development of additional product
candidates and technologies in ophthalmology, including for wet
age-related macular degeneration and diabetic macular edema. More
information is available at www.aeriepharma.com.
Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. We may, in some cases, use terms
such as “predicts,” “believes,” “potential,” “proposed,”
“continue,” “estimates,” “anticipates,” “expects,” “plans,”
“intends,” “may,” “could,” “might,” “will,” “should,” “exploring,”
“pursuing” or other words that convey uncertainty of future events
or outcomes to identify these forward-looking statements.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things: our expectations
regarding the commercialization and manufacturing of Rhopressa® and
Rocklatan™ or any future product candidates, including the timing,
cost or other aspects of the commercial launch of Rhopressa® and
Rocklatan™ or any future product candidates; our commercialization,
marketing, manufacturing and supply management capabilities and
strategies; the success, timing and cost of our ongoing and
anticipated preclinical studies and clinical trials for Rhopressa®
and Rocklatan™, with respect to regulatory approval outside of the
United States or additional indications, and any future product
candidates, including statements regarding the timing of initiation
and completion of the studies and trials; the timing of and our
ability to request, obtain and maintain FDA or other regulatory
authority approval of, or other action with respect to, as
applicable, Rhopressa®, Rocklatan™ or any future product
candidates, including the expected timing of, and timing of
regulatory and/or other review of, filings for, as applicable,
Rhopressa®, Rocklatan™ or any future product candidates; the
potential advantages of Rhopressa® and Rocklatan™ or any future
product candidates; our plans to pursue development of additional
product candidates and technologies within and beyond
ophthalmology; our plans to explore possible uses of our existing
proprietary compounds beyond glaucoma, including development of our
retina program; our ability to protect our proprietary technology
and enforce our intellectual property rights; and our expectations
regarding strategic operations, including our ability to in-license
or acquire additional ophthalmic products, product candidates or
technologies. By their nature, forward-looking statements involve
risks and uncertainties because they relate to events, competitive
dynamics, industry change and other factors beyond our control, and
depend on regulatory approvals and economic and other environmental
circumstances that may or may not occur in the future or may occur
on longer or shorter timelines than anticipated. We discuss many of
these risks in greater detail under the heading “Risk Factors” in
the quarterly and annual reports that we file with the Securities
and Exchange Commission (SEC). In particular, FDA approval of
Rhopressa® and Rocklatan™ do not constitute FDA approval of
AR-1105, AR-13503 or any future product candidates, and there can
be no assurance that we will receive FDA approval for AR-1105,
AR-13503 or any future product candidates. FDA approval of
Rhopressa® and Rocklatan™ also do not constitute regulatory
approval of Rhopressa® and Rocklatan™ in jurisdictions outside the
United States and there can be no assurance that we will receive
regulatory approval for Rhopressa® and Rocklatan™ in jurisdictions
outside the United States. Forward-looking statements are not
guarantees of future performance and our actual results of
operations, financial condition and liquidity, and the development
of the industry in which we operate may differ materially from the
forward-looking statements contained in this press release. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. We assume no obligation
to update our forward-looking statements whether as a result of new
information, future events or otherwise, after the date of this
press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190325005022/en/
Media: Tad Heitmann 949-526-8747;
theitmann@aeriepharma.comInvestors: Ami Bavishi 908-947-3949;
abavishi@aeriepharma.com
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Apr 2023 to Apr 2024